Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03005717 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat
A Phase 2 study of Submental Fat, sponsored by Neothetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
- 11
- Study locations
NCT03005717: Completed Phase 2 study of Submental Fat, sponsored by Neothetics.
NCT03005717 is a Phase 2 study of Submental Fat that has completed, run by Neothetics. The registered enrollment target is 162 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03005717, a Phase 2 study of Submental Fat, has completed, sponsored by Neothetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
- 11
- Study locations
Study Summary
Study LIPO-202-CL-31 is a multi center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of LIPO-202 versus placebo on submental bulging due to subcutaneous fat. Approximately 150 participants of either gender who have a "Moderate Bulge" or "Large Bulge" in the submental fat (on Patient-Reported Submental Bulging Scale \[PR-SBS\] and Clinician-Reported Submental Bulging Scale \[CR-SBS\]) will be recruited for this study.
Conditions Studied
Interventions
- DRUG LIPO-202
- DRUG Placebo for LIPO-202
Study Locations (11)
California
- Clinical Testing of Beverly Hills - Beverly Hills
- Ablon Skin Institute And Research Center - Manhattan Beach
Colorado
- AboutSkin Research - Greenwood Village
Florida
- Skin Research Institute - Coral Gables
Michigan
- Grekin Skin Institute - Warren
Minnesota
- Minnesota Clinical Study Center - Fridley
Missouri
- Mercy Research - Washington
Nebraska
- Skin Specialists, PC - Omaha
New York
- Juva Skin & Laser Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2017-06-02 |
| Phase | Phase 2 |
What the finished NCT03005717 record still lists
NCT03005717 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher).
The record links to 1 condition, with Submental Fat appearing as the primary indexed condition, and to 2 interventions - of which LIPO-202 is the first listed.
NCT03005717 lists 11 locations in 10 states (California, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT03005717 about?
NCT03005717 is a clinical study titled "Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat". Study LIPO-202-CL-31 is a multi center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of LIPO-202 versus placebo on submental bulging due to subcutaneous fat. Approximately 150 participants of either gender who have a "Moderate Bulge" o...
What is the current status of trial NCT03005717?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2016-12-22. Estimated completion is 2017-06-02.
What conditions does trial NCT03005717 study?
This clinical trial studies the following conditions: Submental Fat.
What interventions are being tested in trial NCT03005717?
The interventions under investigation include: LIPO-202 (DRUG), Placebo for LIPO-202 (DRUG).
Who is sponsoring clinical trial NCT03005717?
This trial is sponsored by Neothetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03005717 being conducted?
This trial has 11 study locations across California, Colorado, Florida, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Submental Fat
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03005717's enrollment target sits among peer trials
162 418th of 2000 higher than 1,579 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI